ArticleBiochemistry and biophysics reports2025
Egg-derived sphingomyelin induces ferroptosis in cancer cells, depending on intracellular labile iron pool levels.
Article in Biochemistry and biophysics reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Pathological Mechanisms and Therapeutic Potential of Mitochondrial Dysfunction in Heart Failure.Reviews in cardiovascular medicine · 2026Review
- Lipid Metabolic Mediators Bridge Ischemic Heart Disease and Amyotrophic Lateral Sclerosis.Molecular neurobiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sphingomyelin (SPM), a sphingolipid abundant in animal cell membranes and animal-derived foods, plays a crucial role in maintaining cell membranes and intracellular signaling. Additionally, although previous studies have suggested that SPM has anticancer effects, the molecular entity underlying its effect on cancer cell viability remains unclear. Moreover, the effects of exogenous SPM on cancer cells have not yet been thoroughly explored. In this study, we investigated the mechanisms underlying SPM-induced cell death in cancer cell lines. For the analyses of cell death, we used five cancer cell lines-COV362, AH109A, HepG2, A549, and Colo201-as cancer models and primary cultured rat hepatocytes and normal human dermal fibroblasts (NHDF) as normal cell models. We demonstrated that SPM induces a type of cell death, ferroptosis, in several cancer cell lines, including COV362, AH109A, HepG2, and A549. Furthermore, SPM application increased the production of reactive oxygen species (ROS) and induced ferroptosis. Since one of the key factors regulating ferroptosis sensitivity is the intracellular labile iron pool (LIP), we examined LIP levels in each cell and found that cells with higher LIP levels were more susceptible to SPM-induced cell death; exogenous iron further enhanced this effect, confirming that LIP plays a crucial role in ferroptosis induction. Our findings demonstrate that SPM can selectively induce ferroptosis in cancer cells through ROS production and, possibly, iron-dependent lipid peroxidation. These findings may provide a potential therapeutic strategy for the selective induction of ferroptosis in cancer cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.